Precision NanoSystems Offers Ground-Breaking Transfection Technology for Primary Cells | BioIT World

News Article

March 02, 2017

Bio IT World - Next-Gen Technology | Big Data | Personalized Medicine

VANCOUVER, BC, CANADA - Mar 2, 2017 - Precision NanoSystems is helping scientists to push the boundaries of neuroscience research with a range of efficient and easy-to-use primary cell transfection kits. Combining user-friendly NanoAssemblr™ microfluidics systems with advanced nanoparticle technology, the company has developed the Neuro9™, Astro9™ and iNeuro9™ non-viral gene transfection kits to allow rapid and easy knockdown or expression of genes in primary cells, both in vitro and in vivo.

 

Precision NanoSystems’ innovative transfection kits are optimized for non-viral delivery of short interfering RNA (siRNA), messenger RNA (mRNA) or plasmid DNA (pDNA) into various neural cell types, such as neurons, astrocytes and iPS-derived neurons. This technology offers transfection efficiencies of up to 95 percent with no observed toxicity by taking advantage of an endogenous pathway to deliver the nucleic acid payload. Combined with the company’s NanoAssemblr microfluidic technology, the kits make it fast and easy to reap the benefits of ground-breaking transfection technology.

 

Each kit includes all the reagents required to generate nanoparticles using the NanoAssemblr systems, and is available for either in vitro or in vivo applications. This proven technology ensures rapid, high quality and reproducible results with minimal user training, and has already become widely established in the drug formulation field.

 

To learn more about Precision NanoSystems’ transfection kits or arrange a demo, visit their page on Transfection Kits.


IN THE NEWS

Press Release

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, will participate in BayBio’s 9th Annual Entrepreneur and Investor Roundtab...

Read More


News Article

The commercial availability of microfluidic platforms aimed specifically at drug formulation is helping to lower the barriers to nanomedicine research. Implementation of this technology eliminates the need for in-house microfluidics expertise and e...

Read More